Bortezomib

Bortezomib is an inhibitor of the 26S proteasome, a large protein complex in cells that is responsible for breaking down regulatory proteins of the cell cycle. Such inhibition disrupts tumour cell turnover and induces apoptosis. Bortezomib is used for the treatment of multiple myeloma in patients who have received at least one previous therapy. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.

Bortezomib’s innovator is Millennium Pharmaceuticals, Inc. and is known globally under the brand name Velcade.

The proteasome inhibitors have a unique mechanism of action, and bortezomib is the first compound in this class to reach clinical trials and receive FDA-approval. It has been shown that bortezomib enhances effectiveness of camptothecin therapy and acts as a radiation sensitizer. In addition, infrequent resistances to bortezomib therapy and demonstrated efficacy in the presence of other known drug resistance mechanisms have been shown in preclinical trials. Bortezomib is being studied in non-small cell lung cancer (NSCLC) and colorectal cancer as well as chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndromes (MDS), non-Hodgkin's lymphoma (NHL), pancreatic cancer, gastric cancer, liver cancer, head and neck cancer, melanoma, CNS cancer, breast cancer, prostate cancer, kidney cancer, cervical cancer, and ovarian cancer.

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death.

Bortezomib appears in the formation of Intravenous Powder for Solution in the dosage of 3.5 MG.

General data on Bortezomib Active Pharmaceutical Ingredient

CAS Registry: 179324-69-7
ATC: L01XX32
Molecular Formula: C19H25BN4O4
Molecular Weight: 384.2

TAPI's Bortezomib Pharmaceutical Ingredient

TAPI's Bortezomib Active Pharmaceutical Ingredient is produced in IVAX Pharmaceuticals s.r.o. in Opava-Komarov, Czech Republic.

Bortezomib is produced by TAPI by High Potent Technology synthesis and considered to be low volume Active Pharmaceutical Ingredient.

2008 Available DMF: U.S. DMF

TAPI provide full service on this product and other APIs in our portfolio. Our local sales offices provide full information on our product, regulatory compliance and documentation on Bortezomib. Contact us today for further inquiries and samples and kilograms availability information for TAPI's Bortezomib.

Other products, in the group of ANTINEOPLASTIC AGENTS - Miscellaneous antineoplastics, available on TAPI's portfolio are: Bicalutamide,Etoposide,Fludarabine Phosphate,Fluorouracil and Pemetrexed Diacid. Contact us today for information on these products.

Legal Note

Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer for sale in territories where it is not permitted by law. In USA Products  that  Currently on Patent are available for R&D Use in Accordance with 35 USC §271 (e) (1).

*TAPI stands for Teva's Active Pharmaceutical Ingredients